Big Pharma Puts Profits Over Precaution: FDA Pauses Novavax COVID-Flu Shot Trial

In a troubling development for vaccine manufacturers and proponents of medical mandates, the U.S. Food and Drug Administration (FDA) has put a halt to the trial of Novavax’s combination COVID-19 and influenza vaccine. This decision follows a report of nerve damage in a participant who received the combination shot, raising serious questions about the safety of these rapidly developed vaccines.

As news of the trial pause broke, Novavax’s shares plummeted by nearly 24%, erasing close to $400 million from the company’s market capitalization. This dramatic decline underscores the potential financial repercussions for Novavax and casts a shadow on Novavax’s partnership with French drugmaker Sanofi, which had signed a lucrative deal worth at least $1.2 billion to co-sell Novavax’s vaccines. 

The participant, who was enrolled in a mid-stage study, reported symptoms of motor neuropathy—an alarming condition affecting nerve cells that control muscle movement. Although Novavax has indicated that the connection between the vaccine and the reported injury has not been established, the pause serves as a stark reminder of the risks associated with these experimental products.

Novavax expressed a desire to resolve the matter swiftly, stating, “it was working with the FDA to resolve the pause.” Their focus on profits and resolving the pause, NOT resolving the safety issue, could have broader implications for the vaccine industry amidst ongoing public skepticism.

As more data is required to address the FDA’s safety concerns, the vaccine mandate advocates should take note: this incident highlights the importance of scrutiny and caution when it comes to medical interventions. The pause in Novavax’s trial is a critical reminder of the potential dangers of rushing vaccines to market without thorough evaluation.

Texans for Vaccine Choice stands firmly against any form of medical mandates, whether imposed by the government or private entities. We believe that individuals should have the freedom to make informed vaccine choices without fear of retribution or coercion. 

The recent developments surrounding Novavax’s trial reinforce our stance against medical tyranny. It is imperative that we demand accountability and transparency from vaccine manufacturers since the fight against medical mandates is far from over.